Cerebrospinal fluid alpha-synuclein as a biomarker for Parkinson's disease diagnosis: a systematic review and meta-analysis

No abstract is available for this paper.

• Publication year

  2015

• Venue

  International Journal of Neuroscience

• Publication date

  2015-09-02

• Fields of study

  Medicine

• Identifiers
  DOI 10.3109/00207454.2014.961454PMID 25202803
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• [Parkinson's disease].

  2022cited by this paper
• Circulating MicroRNAs as a Novel Class of Diagnostic Biomarkers in Gastrointestinal Tumors Detection: A Meta-Analysis Based on 42 Articles

  2014influential reference
• Reduced α‐synuclein levels in cerebrospinal fluid in Parkinson's disease are unrelated to clinical and imaging measures of disease severity

  2014cited by this paper
• Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease.

  2013cited by this paper
• CSF α-synuclein improves diagnostic and prognostic performance of CSF tau and Aβ in Alzheimer’s disease

  2013cited by this paper
• Low CSF Levels of Both α-Synuclein and the α-Synuclein Cleaving Enzyme Neurosin in Patients with Synucleinopathy

  2013cited by this paper
• [Epidemiology of Parkinson's disease].

  2013cited by this paper
• Total CSF α-synuclein is lower in de novo Parkinson patients than in healthy subjects.

  2013cited by this paper
• Phosphorylated alpha-Synuclein in Parkinson's Disease

  2012cited by this paper
• Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders.

  2012influential reference
• Alpha-synuclein in the Cerebrospinal Fluid Differentiates Synucleinopathies (Parkinson Disease, Dementia With Lewy Bodies, Multiple System Atrophy) From Alzheimer Disease

  2012cited by this paper
• Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease

  2011cited by this paper
• Biomarker candidates of neurodegeneration in Parkinson’s disease for the evaluation of disease-modifying therapeutics

  2011cited by this paper
• Elevated Levels of α-Synuclein Oligomer in the Cerebrospinal Fluid of Drug-Naïve Patients with Parkinson's Disease

  2011cited by this paper
• QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy Studies

  2011cited by this paper
• CSF levels of oligomeric alpha-synuclein and beta-amyloid as biomarkers for neurodegenerative disease.

  2011cited by this paper
• α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.

  2011influential reference
• Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression

  2011influential reference
• Cerebrospinal fluid Tau/α‐synuclein ratio in Parkinson's disease and degenerative dementias

  2011influential reference
• Olfaction as a biomarker in Parkinson's disease.

  2010cited by this paper
• CSF α-Synuclein Does Not Discriminate Dementia with Lewy Bodies from Alzheimer's Disease

  2010cited by this paper
• Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease

  2010cited by this paper
• Quantification of α-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies.

  2010cited by this paper
• Detection of elevated levels of -synuclein oligomers in CSF from patients with Parkinson disease

  2010cited by this paper
• DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease.

  2010cited by this paper
• Cerebrospinal fluid a-synuclein in neurodegenerative disordersA marker of synapse loss?

  2009cited by this paper
• Biological fluid biomarkers in neurodegenerative parkinsonism

  2009cited by this paper
• Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration.

  2008cited by this paper
• Second consensus statement on the diagnosis of multiple system atrophy

  2008influential reference
• Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease.

  2006cited by this paper
• Decreased α-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson’s disease.

  2006cited by this paper
• Epidemiology of Parkinson's disease.

  2006cited by this paper
• α-Synuclein structure, posttranslational modification and alternative splicing as aggregation enhancers

  2006cited by this paper
• Diagnosis and management of dementia with Lewy bodies

  2005cited by this paper
• Neuroimaging trials of Parkinson’s disease progression

  2004cited by this paper
• Clinical overview of the synucleinopathies

  2003cited by this paper
• Parkinson's disease. Second of two parts.

  1998cited by this paper
• Parkinson's disease. First of two parts.

  1998cited by this paper
• A clinicopathologic study of 100 cases of Parkinson's disease.

  1993cited by this paper
• Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

  1992cited by this paper
• Accuracy in the clinical diagnosis of parkinsonian syndromes.

  1988cited by this paper
• Clinical diagnosis of Alzheimer's disease

  1984cited by this paper

• Alpha-Synuclein in Neurodegeneration: From Shared Biology to Disease-Specific Phenotypes

  2026cites this paper
• Porous Materials for Early Diagnosis of Neurodegenerative Diseases

  2025cites this paper
• Alpha‐Synuclein as a Potential Biomarker for Inclusion Body Myositis in Blood and Muscle

  2025cites this paper
• The potential of erythrocyte α-synuclein to differentiate dementia with Lewy bodies from Parkinson's and Alzheimer's diseases.

  2025cites this paper
• Toward a biological definition of neuronal and glial synucleinopathies

  2025cites this paper
• Bioanalytical Considerations for Biomarkers of Parkinson's Disease

  2025cites this paper
• Physics of Protein Aggregation in Normal and Accelerated Brain Aging

  2025cites this paper
• Marqueurs biologiques des maladies neurodégénératives

  2025cites this paper
• Deciphering the role of neuropeptides as biomarkers for early diagnosis of Parkinson's disease.

  2025cites this paper
• A High-Throughput ImmunoHistoFluorescence (IHF) Method for Sub-Nuclear Protein Analysis in Tissue

  2025cites this paper
• The Search for Disease Modification in Parkinson’s Disease—A Review of the Literature

  2025cites this paper
• Advances in Circulating Biomarkers for Neurodegenerative Diseases, Traumatic Brain Injuries, and Central Nervous System Tumors

  2025cites this paper
• Biomarkers and neuroimaging markers in Parkinson’s disease

  2025cites this paper
• The Utilization of An Artificial Intelligence and Machine Learning Model to Aid in Accelerating Parkinson’s Disease Diagnosis

  2025cites this paper
• Dysregulation of melatonin rhythm in Parkinson’s and Huntington’s disease: a systematic review and meta-analysis

  2025influential citation
• Marcatori biologici delle malattie neurodegenerative

  2025cites this paper
• A systematic review and meta-analysis on glymphatic flow dysfunction in Parkinson’s disease and Parkinsonism spectrum

  2025cites this paper
• Staging and markers in Parkinson’s disease and Lewy body disorders: narrative review

  2025cites this paper
• Using machine learning for detection of Parkinson’s disease and mild cognitive impairment

  2025cites this paper
• Summarizing the Role of Selected Adipokines in Parkinson’s Disease: What Is Known About Leptin, Adiponectin, Resistin, Visfatin, and Progranulin in Neurodegeneration?

  2025cites this paper
• Diagnostic biomarkers for α-synucleinopathies- state of the art and future developments: a systematic review

  2025influential citation
• Microfluidic platform for understanding Parkinson’s disease and α-synuclein conformation

  2025cites this paper
• Current Status of α-Synuclein Biomarkers and the Need for α-Synuclein PET Tracers

  2025cites this paper
• Refining the clinical diagnosis of Parkinson's disease.

  2024cites this paper
• Potential biofluid markers for cognitive impairment in Parkinson’s disease

  2024cites this paper
• α‐Synuclein Gene Hypomethylation in LRRK2 Parkinson's Disease Patients

  2024cites this paper
• α-Synuclein Oligomers in Skin Biopsies Predict the Worsening of Cognitive Functions in Parkinson’s Disease: A Single-Center Longitudinal Cohort Study

  2024cites this paper
• The effect of a nicotine-rich diet with/without redistribution of dietary protein on motor indices in patients with Parkinson's disease: A randomized clinical trial.

  2024cites this paper
• Navigating the Neurobiology of Parkinson’s: The Impact and Potential of α-Synuclein

  2024cites this paper
• Research advancement in fluid biomarkers for Parkinson’s disease

  2024cites this paper
• The Role of α-Synuclein in Etiology of Neurodegenerative Diseases

  2024cites this paper
• Tear α-synuclein as a biomarker for Parkinson's disease: A systematic review and meta-analysis

  2024cites this paper
• Evolving insights into erythrocytes in synucleinopathies.

  2024cites this paper
• Clinical and diagnostic implications of Alzheimer's disease copathology in Lewy body disease.

  2024cites this paper
• Serum Oligomeric α-Synuclein and p-tau181 in Progressive Supranuclear Palsy and Parkinson’s Disease

  2024cites this paper
• An interactive web application to identify early Parkinsonian non-tremor-dominant subtypes

  2024cites this paper
• Biosensors for α-synuclein detection: Towards an improved diagnosis of Parkinson's disease

  2023cites this paper
• Plasma Alpha Synuclein as a Potent Biomarker of Diseases with Synucleinopathies

  2023cites this paper
• Single-Molecule Detection of α-Synuclein Oligomers in Parkinson’s Disease Patients Using Nanopores

  2023cites this paper
• Cerebrospinal fluid biomarkers profile in scans without evidence of dopaminergic deficits (SWEDD)

  2023cites this paper
• How should we be using biomarkers in trials of disease modification in Parkinson’s disease?

  2023cites this paper
• Uninterrupted real‐time cerebral stress level monitoring using wearable biosensors: A review

  2023cites this paper
• Elevated ApoE, ApoJ and lipoprotein-bound α-synuclein levels in cerebrospinal fluid from Parkinson’s disease patients – Validation in the BioFIND cohort

  2023cites this paper
• Parkinson's disease is positively associated with periodontal inflammation.

  2023cites this paper
• Lewy body disease as a potential negative outcome modifier of glioblastoma treatment: a case report

  2023cites this paper
• Microglia‐specific knock‐out of NF‐κB/IKK2 increases the accumulation of misfolded α‐synuclein through the inhibition of p62/sequestosome‐1‐dependent autophagy in the rotenone model of Parkinson's disease

  2023cites this paper
• Fluid and Biopsy Based Biomarkers in Parkinson’s Disease

  2023cites this paper
• CSF neurochemical profile and cognitive changes in Parkinson’s disease with mild cognitive impairment

  2023cites this paper
• Cognitive heterogeneity in Parkinson's disease: A mechanistic view.

  2023cites this paper
• Role of novel endpoints and evaluations of response in Parkinson disease.

  2023cites this paper
• Does TRODAT-1 SPECT Uptake Correlate with Cerebrospinal Fluid α-Synuclein Levels in Mid-Stage Parkinson’s Disease?

  2023cites this paper
• Searching for Biomarkers in the Blood of Patients at Risk of Developing Parkinson’s Disease at the Prodromal Stage

  2023cites this paper
• Seed amplification assay for the detection of pathologic alpha-synuclein aggregates in cerebrospinal fluid

  2023cites this paper
• Unravelling the genetic links between Parkinson’s disease and lung cancer

  2023cites this paper
• Diffusion along perivascular spaces as marker for impairment of glymphatic system in Parkinson’s disease

  2022cites this paper
• Investigating neurological symptoms of infectious diseases like COVID-19 leading to a deeper understanding of neurodegenerative disorders such as Parkinson's disease

  2022cites this paper
• SWATH Mass Spectrometry-Based CSF Proteome Profile of GBA-Linked Parkinson’s Disease Patients

  2022cites this paper
• Regulation of α-synuclein homeostasis and inflammasome activation by microglial autophagy

  2022cites this paper
• CSF α-Synuclein and Tau as Biomarkers for Dementia With Lewy Bodies

  2022cites this paper
• Opportunities and challenges of alpha-synuclein as a potential biomarker for Parkinson’s disease and other synucleinopathies

  2022cites this paper
• Monocyte biomarkers define sargramostim treatment outcomes for Parkinson's disease

  2022cites this paper
• Evaluation of Alpha-Synuclein Cerebrospinal Fluid Levels in Several Neurological Disorders

  2022cites this paper
• Electrochemical Aptasensors for Parkinson's Disease Biomarkers Detection.

  2022cites this paper
• Dysregulation of a Heme Oxygenase–Synuclein Axis in Parkinson Disease

  2022cites this paper
• Alpha and Beta Synucleins: From Pathophysiology to Clinical Application as Biomarkers

  2022cites this paper
• Baseline Cerebrospinal Fluid α-Synuclein in Parkinson’s Disease Is Associated with Disease Progression and Cognitive Decline

  2022cites this paper
• Biomarker of Neuroinflammation in Parkinson’s Disease

  2022cites this paper
• Rotenone induces regionally distinct α-synuclein protein aggregation and activation of glia prior to loss of dopaminergic neurons in C57Bl/6 mice.

  2022cites this paper
• Fluid markers of synapse degeneration in synucleinopathies

  2022cites this paper
• Characterization of molecular biomarkers in cerebrospinal fluid and serum of E46K-SNCA mutation carriers.

  2022cites this paper
• Parkinson's disease fluid biomarkers for differential diagnosis of atypical parkinsonian syndromes

  2022cites this paper
• Synuclein in neurodegeneration.

  2021cites this paper
• Biosensor approaches on the diagnosis of neurodegenerative diseases: Sensing the past to the future.

  2021cites this paper
• Sporadic Creutzfeldt-Jakob disease: Real-Time Quaking-Induced Conversion (RT-QuIC) assay represents a major diagnostic advance

  2021cites this paper
• Alfa-sinukleina biomarkatzaile gisa Parkinson gaixotasunaren diagnostikoan (Alpha-synuclein

  2021cites this paper
• Extracellular Vesicles for the Diagnosis and Treatment of Parkinson’s Disease

  2021cites this paper
• Biomarker in Parkinson’s Disease: Clinical and Biochemical Biomarker

  2021cites this paper
• Ultrasensitive techniques and protein misfolding amplification assays for biomarker-guided reconceptualization of Alzheimer’s and other neurodegenerative diseases

  2021cites this paper
• Current advances in metabolomic studies on non-motor psychiatric manifestations of Parkinson's disease (Review)

  2021cites this paper
• Alpha-Synuclein as a Biomarker of Parkinson’s Disease: Good, but Not Good Enough

  2021cites this paper
• Cerebrospinal Fluid Biomarkers in Multiple System Atrophy Relative to Parkinson's Disease: A Meta-Analysis

  2021cites this paper
• Identification of the Raman Salivary Fingerprint of Parkinson’s Disease Through the Spectroscopic– Computational Combinatory Approach

  2021cites this paper
• Cerebrospinal fluid hemoglobin levels as markers of blood contamination: relevance for α-synuclein measurement

  2021cites this paper
• A Pilot Study of Changes in the Level of Catecholamines and the Activity of α-2-Macroglobulin in the Tear Fluid of Patients with Parkinson’s Disease and Parkinsonian Mice

  2021cites this paper
• Alpha-synuclein seeds in olfactory mucosa and cerebrospinal fluid of patients with dementia with Lewy bodies

  2021cites this paper
• Cognitive Impairment in Genetic Parkinson's Disease

  2021cites this paper
• Response to the Letter to the Editor by Tomoyuki Kawada: "Alpha-Synuclein Levels in Cerebrospinal Fluid in Patients With Lewy Bodies Dementia and Other Neurodegenerative Disorders".

  2021cites this paper
• Preanalytical Stability of CSF Total and Oligomeric Alpha-Synuclein

  2021cites this paper
• Ecto-GPR37: a potential biomarker for Parkinson’s disease

  2021cites this paper
• Fluid Candidate Biomarkers for Alzheimer’s Disease: A Precision Medicine Approach

  2020cites this paper
• Plasma and Serum Alpha-Synuclein as a Biomarker of Diagnosis in Patients With Parkinson's Disease

  2020cites this paper
• APOE genotype regulates pathology and disease progression in synucleinopathy

  2020cites this paper
• Tears - more to them than meets the eye: why tears are a good source of biomarkers in Parkinson's disease.

  2020cites this paper
• The path to biomarker-based diagnostic criteria for the spectrum of neurodegenerative diseases

  2020cites this paper
• Methods for detecting toxic α-synuclein species as a biomarker for Parkinson’s disease

  2020cites this paper
• Prodromal PD: A new nosological entity.

  2020cites this paper
• An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders

  2020cites this paper
• New markers in Parkinson's disease.

  2020cites this paper
• Biofluid Biomarkers in Parkinson's Disease: Clarity Amid Controversy

  2020cites this paper
• Peripheral alpha-synuclein levels in patients with genetic and non-genetic forms of Parkinson's disease.

  2020cites this paper